Blog · GxP practical knowledge
GxP, AI and validation — without the show.
The traqx blog explains how regulated teams can use AI without giving up traceability, data control or QA responsibility.
Articles and field materials
GxP AI policy: what a workable AI use policy should control
From initial screening to data, human review and audit trail: ten building blocks, three decision lanes and a usable policy core for regulated teams.
FDA Elsa 4.0 and HALO: what GxP companies need to know
Elsa 4.0 is already in use. We separate confirmed FDA facts from speculation and show how teams can prepare sources, human review and decisions for faster scrutiny.
10 GxP AI prompt patterns for controlled work
Ten complete work patterns for SOPs, CSV, audit preparation, CAPA and other GxP tasks — each with a source boundary, review question and explicit stop condition.
Assessing GxP AI: 12 questions before use
A practical decision framework for QA, CSV and IT: twelve questions, a compact decision sheet and clear warning signs before AI is introduced into a GxP process.
FDA warning letter on AI agents: what Quality Units now need to prove
FDA cited unreviewed AI-generated GMP documents and delegated subject-matter responsibility. What the case actually shows — and which controls Quality Units should take from it.
AI-native GxP software, eQMS or consulting — what fits when?
AI-native platform, classic eQMS or pure consulting? What each category delivers, where the evidence difference lies — and when each one fits.
ALCOA+: the nine principles of data integrity
Five classical ALCOA criteria plus four extensions — what each requires, how they connect and what applies once AI contributes to GxP records.
Validating AI/ML systems under GAMP 5: the practical path
Intended use, independent test data, a model lifecycle instead of a cut-off date, drift monitoring and human oversight — the applied validation path for models.
EU GMP Annex 11: what computerised systems need to demonstrate
The applicable 2011 version, risk-based validation, audit trails, supplier oversight and the status of the 2025 revision — without mixing draft and current requirements.
Annex 22 vs Annex 11: how the AI annex complements GMP systems
Annex 11 is the applicable system framework; Annex 22 is the draft for additional AI controls. What each covers and how to prepare without treating the draft as current law.
EU AI Act × GxP: what the AI Act means for regulated pharma quality
The AI Act does not replace GxP — it lays a second layer over AI systems. Where the governance overlaps and what you can prepare before the legal picture is final.
Using AI in GxP — without giving up control
Is AI allowed in GxP? Long answered — the question is how controlled. The practical guide: draft Annex 22, GAMP 5, FDA CSA and the five principles that keep every result evidenced.
EU GMP Annex 22: what the first AI annex means for your GxP practice
Static models, human oversight, independent test data, explainability: what the draft requires — and how to prepare today.
GAMP 5 2nd Edition: What CSV now needs
The Second Edition modernizes CSV: critical thinking, agile lifecycles, cloud and AI. What you need to adjust — and what not.
CSA vs CSV: What the FDA Final Guidance means for your validation strategy
Computer Software Assurance supersedes CSV: less documentation, more critical thinking. What the FDA guidance means for your strategy.
Make Computer System Validation more predictable: The pragmatic guide
Make CSV more predictable — clear phases, risk-based test depth and evidence that is not assembled only at the end.
Blog content is guidance, not legal or compliance advice.